Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

avpak - buprenorphine hydrochloride (unii: 56w8mw3en1) (buprenorphine - unii:40d3scr4gz), naloxone hydrochloride dihydrate (unii: 5q187997ee) (naloxone - unii:36b82amq7n) - buprenorphine 2 mg - buprenorphine and naloxone sublingual tablets are indicated for the maintenance treatment of opioid dependence. buprenorphine and naloxone sublingual tablets should be used as part of a complete treatment plan that includes counseling and psychosocial support. buprenorphine and naloxone sublingual tablets are contraindicated in patients with a history of hypersensitivity to buprenorphine or naloxone as serious adverse reactions, including anaphylactic shock, have been reported [see warnings and precautions (5.9)] . risk summary the data on use of buprenorphine, one of the active ingredients in buprenorphine and naloxone sublingual tablets, in pregnancy, are limited; however, these data do not indicate  an increased risk of major malformations specifically due to buprenorphine exposure. there are limited data from randomized clinical trials in women maintained on buprenorphine that were not designed appropriately to assess the risk of major malformations [see data] . observational st

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

specgx llc - buprenorphine hydrochloride (unii: 56w8mw3en1) (buprenorphine - unii:40d3scr4gz), naloxone hydrochloride dihydrate (unii: 5q187997ee) (naloxone - unii:36b82amq7n) - buprenorphine 2 mg - buprenorphine and naloxone sublingual tablets are indicated for the maintenance treatment of opioid dependence. buprenorphine and naloxone sublingual tablets should be used as part of a complete treatment plan that includes counseling and psychosocial support. buprenorphine and naloxone sublingual tablets are contraindicated in patients with a history of hypersensitivity to buprenorphine or naloxone as serious adverse reactions, including anaphylactic shock, have been reported [see warnings and precautions (5.9)] . risk summary the data on use of buprenorphine, one of the active ingredients in buprenorphine and naloxone sublingual tablets, in pregnancy, are limited; however, these data do not indicate  an increased risk of major malformations specifically due to buprenorphine exposure. there are limited data from randomized clinical trials in women maintained on buprenorphine that were not designed appropriately to assess the risk of major malformations [see data] . observational studies have reported on cong

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

avkare, inc. - buprenorphine hydrochloride (unii: 56w8mw3en1) (buprenorphine - unii:40d3scr4gz), naloxone hydrochloride dihydrate (unii: 5q187997ee) (naloxone - unii:36b82amq7n) - buprenorphine 2 mg - buprenorphine and naloxone sublingual tablets are indicated for the maintenance treatment of opioid dependence. buprenorphine and naloxone sublingual tablets should be used as part of a complete treatment plan that includes counseling and psychosocial support. buprenorphine and naloxone sublingual tablets are contraindicated in patients with a history of hypersensitivity to  buprenorphine or naloxone as serious adverse reactions, including anaphylactic shock, have been reported [see warnings and precautions (5.9)] . risk summary the data on use of buprenorphine, one of the active ingredients in buprenorphine and naloxone sublingual tablets, in pregnancy, are limited; however, these data do not indicate  an increased risk of major malformations specifically due to buprenorphine exposure. there are limited data from randomized clinical trials in women maintained on buprenorphine that were not designed appropriately to assess the risk of major malformations

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

physicians total care, inc. - buprenorphine hydrochloride (unii: 56w8mw3en1) (buprenorphine - unii:40d3scr4gz), naloxone hydrochloride (unii: f850569pqr) (naloxone - unii:36b82amq7n) - buprenorphine hydrochloride 2 mg - suboxone and subutex are indicated for the treatment of opioid dependence. suboxone and subutex should not be administered to patients who have been shown to be hypersensitive to buprenorphine, and suboxone should not be administered to patients who have been shown to be hypersensitive to naloxone. suboxone and subutex are controlled as schedule iii narcotics under the controlled substances act. buprenorphine is a partial agonist at the mu-opioid receptor and chronic administration produces dependence of the opioid type, characterized by moderate withdrawal upon abrupt discontinuation or rapid taper. the withdrawal syndrome is milder than seen with full agonists, and may be delayed in onset (see warnings) neonatal withdrawal has been reported in the infants of women treated with subutex during pregnancy (see precautions) suboxone contains naloxone and if misused parenterally, is highly likely to produce marked and intense withdrawal symptoms in subjects dependent on other opioid agonists.

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

quality care products, llc - buprenorphine hydrochloride (unii: 56w8mw3en1) (buprenorphine - unii:40d3scr4gz), naloxone hydrochloride (unii: f850569pqr) (naloxone - unii:36b82amq7n) - buprenorphine 8 mg - suboxone sublingual film is indicated for treatment of opioid dependence . suboxone sublingual film should be used as part of a complete treatment plan that includes counseling and psychosocial support. suboxone sublingual film is contraindicated in patients with a history of hypersensitivity to buprenorphine or naloxone as serious adverse reactions, including anaphylactic shock, have been reported [see warnings and precautions (5.9)] . risk summary the data on use of buprenorphine, one of the active ingredients in suboxone sublingual film, in pregnancy, are limited; however, these data do not indicate an increased risk of major malformations specifically due to buprenorphine exposure. there are limited data from randomized clinical trials in women maintained on buprenorphine that were not designed appropriately to assess the risk of major malformations [see data]. observational studies have reported on congenital malformations among buprenorphine-exposed pregnancies, but were also not designed appropriately

Велика Британија - Енглески - MHRA (Medicines & Healthcare Products Regulatory Agency)

hameln pharma ltd - naloxone hydrochloride dihydrate - solution for injection - 400microgram/1ml

Велика Британија - Енглески - MHRA (Medicines & Healthcare Products Regulatory Agency)

aop orphan ltd - naloxone hydrochloride dihydrate - solution for injection - 400microgram/1ml

Нови Зеланд - Енглески - Medsafe (Medicines Safety Authority)

juno pharmaceuticals nz limited - naloxone hydrochloride dihydrate 440 µg/ml (equiv naloxone hydrochloride 400µg/ml) - solution for injection - 400 mcg/ml - active: naloxone hydrochloride dihydrate 440 µg/ml (equiv naloxone hydrochloride 400µg/ml) excipient: hydrochloric acid water for injection - complete or partial reversal of opioid depression, including respiratory depression, induced by opioids including natural and synthetic opioids, propoxyphene, methadone and the narcotic-antagonist analgesics: nalbuphine, pentazocine and butorphanol. naloxone hydrochloride dihydrate injection is also indicated for the diagnosis of suspected acute opioid overdosage.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

aa-med pty ltd - buprenorphine hydrochloride,naloxone hydrochloride dihydrate -

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

aa-med pty ltd - buprenorphine hydrochloride,naloxone hydrochloride dihydrate -